For people with type 1 diabetes

INNODIA brings together diabetes experts from across Europe and is conducting a study in type1 diabetes to discover new factors to predict the risk of developing the disease, and new treatments and ways of preserving insulin production. Getting a more complete view on different ‘biomarkers’, ie factors in your blood, urine or stool, that can predict the development and evolution of type 1 diabetes, is crucial for a better and earlier diagnosis for people at risk to developing the disease as well as for a better follow-up and eventually finding a cure for the patients.

Such biomarkers can by identified by analyzing your blood, urine and stool samples.

In the first phase of the project, INNODIA recruited children and adults across Europe aged between 1 and 45 years who had been diagnosed with type 1 diabetes within the previous 6 weeks, called an observational study.

Recruitment target has now been reached!

Thank you to all people with type 1 diabetes who already had their final INNODIA visit and those who are still participating in this project! Your contribution is crucial for type 1 diabetes research.

In the next phase; the collected samples and data will be examined in great detail.

Clinical trials

People with newly diagnosed type 1 diabetes (maximum 6 weeks after diagnosis) can now take part in research that aims to generate knowledge helping to arrest further disease development. The aim of these studies is to halt the further decline in beta cell functionality in people with newly diagnosed T1D, addressing the immune system or the beta cells by different treatment modalities.

Read more

Recently diagnosed with type 1 diabetes?

For people diagnosed with T1D over the past 6 weeks, we offer clinical studies testing ways to slow disease progression by preserving insulin production. If you think you might be eligible to take part, please get in touch by clicking the button below.

How can I participate to INNODIA?

Listen to DELTA!

Research related publications

Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1.

Gene expression signatures of target issues in type 1 diabetes.

A humanized mouse Strain that develops spontaneously immune-mediated diabetes.

Targeting protein changes to cure autoimmune diseases: how far are we from clinical translation?

MDA5 is involved in type 1 diabetes pathogenesis; what does that mean?

How do we want to arrest type 1 diabetes?
The late Prof. David Dunger - University of Cambridge
Patient Perspective in INNODIA
Olivier Arnaud - JDRF